TN 201
Alternative Names: TN-201Latest Information Update: 22 Dec 2025
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference; Myosin-binding protein C replacements
-
Orphan Drug Status
Yes - Hypertrophic cardiomyopathy
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hypertrophic cardiomyopathy
Most Recent Events
- 12 Dec 2025 The US FDA has removes the clinical hold on the MyPEAK-1™ phase Ib/IIa trial of TN 201
- 10 Nov 2025 Pharmacodynamics and pharmacokinetics data from a phase I/II MyPEAK-1 trial in hypertrophic cardiomyopathy released by Tenaya Therapeutics
- 10 Nov 2025 Updated efficacy, adverse events and pharmacodynamic data from a I/II MyPEAK-1 trial in hypertrophic cardiomyopathy released by Tenaya Therapeutics